Central lymph node metastasis is predictive of survival in advanced gastric cancer patients treated with D2 lymphadenectomy

[1]  H. Liang,et al.  Clinical significance of skip lymph-node metastasis in pN1 gastric-cancer patients after curative surgery , 2019, Gastroenterology report.

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  J. Ajani,et al.  Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy , 2018, Journal of Gastrointestinal Surgery.

[4]  J. Ajani,et al.  Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer , 2017, Journal of Gastrointestinal Surgery.

[5]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[6]  Y. Seto,et al.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma , 2017, Gastric Cancer.

[7]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology , 2016 .

[8]  Yuan Ji,et al.  Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX) , 2016, Oncotarget.

[9]  H. Putter,et al.  Quality control of lymph node dissection in the Dutch Gastric Cancer Trial , 2015, The British journal of surgery.

[10]  S. Mocellin,et al.  Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials. , 2015, Cancer treatment reviews.

[11]  F. Huang,et al.  Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials , 2015, European Journal of Clinical Pharmacology.

[12]  He Yulong,et al.  A New pN Staging System Based on Both the Number and Anatomic Location of Metastatic Lymph Nodes in Gastric Cancer , 2014, Journal of Gastrointestinal Surgery.

[13]  A. Nashimoto,et al.  Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis , 2014, The British journal of surgery.

[14]  X. Qin,et al.  A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis , 2014, Cancer Chemotherapy and Pharmacology.

[15]  S. Choi,et al.  Anatomic Extent of Metastatic Lymph Nodes: Still Important for Gastric Cancer Prognosis , 2014, Annals of Surgical Oncology.

[16]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Griniatsos,et al.  Clinical Implications of the Histologically and Immunohistochemically Detected Solitary Lymph Node Metastases in Gastric Cancer , 2011, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[18]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.

[19]  K. Chijiiwa,et al.  Comparative effect of lymph node metastasis classified by the anatomical site or by the number of nodes involved on prognosis of patients with gastric cancer. , 2008, Hepato-gastroenterology.

[20]  Y. Mok,et al.  Impact of skip metastasis in gastric cancer , 2005, ANZ journal of surgery.

[21]  P. Fockens,et al.  Lymphatic drainage routes of the gastric cardia visualized by lymphoscintigraphy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. Klimstra,et al.  Lymph Node Staging in Gastric Cancer: Is Location More Important Than Number?: An Analysis of 1,038 Patients , 2000, Annals of surgery.

[23]  H. Katai,et al.  Evaluation of the new international union against cancer TNM staging for gastric carcinoma , 2000, Cancer.

[24]  H. Shimada,et al.  Superiority of a new UICC-TNM staging system for gastric carcinoma. , 2000, Surgery.

[25]  L. Rikkers,et al.  The society for surgery of the alimentary tract postgraduate course , 1991 .

[26]  H. Stützer,et al.  Has there been any improvement in the staging of gastric cancer?. Findings from the German gastric cancer TNM study group , 1989, Cancer.

[27]  J. Henzen.  Publisher's note , 1979, Brain Research.

[28]  Quan P. Ly,et al.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[29]  Yoon Young Choi,et al.  Skip lymph node metastasis in gastric cancer: is it skipping or skipped? , 2015, Gastric Cancer.

[30]  Japanese Gastric Cancer Association.  Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.

[31]  日本胃癌学会.  Gastric cancer : official journal of the International Gastric Cancer Association and Japanese Gastric Cancer Association , 1998 .

[32]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .